Royal Bank of Canada’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Royal Bank of Canada’s Portfolio LABU Stock Details LABU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-545	Closed	-$51K	–	7403
2025 Q3	$51K	Hold	545	–	–	﹤0.01%	5812
2025 Q2	$31K	Buy	+545	New	+$28.9K	﹤0.01%	6118
2024 Q1	–	Sell	-20	Closed	-$2K	–	7314
2023 Q4	$2K	Buy	+20	New	+$1.53K	﹤0.01%	6814
2023 Q3	–	Sell	-5	Closed	-$1K	–	7336
2023 Q2	$1K	Hold	5	–	–	﹤0.01%	7023
2023 Q1	$0	Hold	5	–	–	﹤0.01%	7281
2022 Q4	$1K	Hold	5	–	–	﹤0.01%	7043
2022 Q3	$1K	Hold	5	–	–	﹤0.01%	7211
2022 Q2	$1K	Hold	5	–	–	﹤0.01%	7146
2022 Q1	$2K	Hold	5	–	–	﹤0.01%	7486
2021 Q4	$4K	Hold	5	–	–	﹤0.01%	7277
2021 Q3	$6K	Hold	5	–	–	﹤0.01%	7083
2021 Q2	$7K	Hold	5	–	–	﹤0.01%	6977
2021 Q1	$8K	Hold	5	–	–	﹤0.01%	6893
2020 Q4	$10K	Hold	5	–	–	﹤0.01%	6375
2020 Q3	$5K	Hold	5	–	–	﹤0.01%	6133
2020 Q2	$6K	Hold	5	–	–	﹤0.01%	5993
2020 Q1	$2K	Buy	+5	New	+$4.55K	﹤0.01%	6304
2017 Q3	–	Sell	-15	Closed	-$19K	–	6839
2017 Q2	$19K	Buy	+15	New	+$15.1K	﹤0.01%	5558

Other funds holding LABU

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

MIG

McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Royal Bank of Canada's LABU Position: Q4 2025 in Review

Royal Bank of Canada sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2025, closing a stake of 545 shares — an estimated $51K sold.

Royal Bank of Canada first reported a position in LABU in Q2 2017 and held it in 18 quarters. The position peaked at $51K in Q3 2025. 40 funds tracked by Wall St. Rank hold LABU as of Q4 2025.

Royal Bank of Canada reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2025 after selling out during the quarter.
Royal Bank of Canada sold 545 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2025, an estimated $51K.
Royal Bank of Canada first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2017 and held it in 18 quarters.
Royal Bank of Canada's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $51K in Q3 2025.
40 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2025.

Based on Royal Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.